tiprankstipranks
MaaT Pharma (FR:MAAT)
:MAAT
France Market

MaaT Pharma (MAAT) Technical Analysis

Compare
2 Followers

Summary of all the Indicators

Overall Consensus
Sell
6Bullish
1Neutral
15Bearish
Technical Analysis Consensus
Buy
6Bullish
1Neutral
3Bearish
Moving Average Consensus
Strong Sell
0Bullish
0Neutral
12Bearish
MaaT Pharma’s (MAAT) Moving Averages Convergence Divergence (MACD) indicator is -0.35, suggesting MaaT Pharma is a Buy.
MaaT Pharma’s (MAAT) 20-Day exponential moving average is 7.02, while MaaT Pharma’s (MAAT) share price is €6.36, making it a Sell.
MaaT Pharma’s (MAAT) 50-Day exponential moving average is 7.42, while MaaT Pharma’s (MAAT) share price is €6.36, making it a Sell.

MaaT Pharma (MAAT) Pivot Points

Mar 03, 2025, 11:59 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
6.05
6.23
6.31
6.49
6.57
6.75
6.83
Fibonacci
6.23
6.33
6.39
6.49
6.59
6.65
6.75
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

MaaT Pharma (MAAT) Moving Averages

Mar 03, 2025, 11:59 PM
Period
Simple
Exponential
MA5
6.54Sell
6.53Sell
MA10
6.75Sell
6.72Sell
MA20
7.05Sell
7.02Sell
MA50
7.66Sell
7.42Sell
MA100
7.65Sell
7.58Sell
MA200
7.54Sell
7.77Sell
MaaT Pharma’s (MAAT) 10-Day exponential moving average is 6.72, while MaaT Pharma’s (MAAT) share price is €6.36, making it a Sell.
MaaT Pharma’s (MAAT) 100-Day exponential moving average is 7.58, while MaaT Pharma’s (MAAT) share price is €6.36, making it a Sell.
MaaT Pharma’s (MAAT) stock price is €6.36 and MaaT Pharma’s (MAAT) 50-day simple moving average is 7.66, creating a Sell signal.
MaaT Pharma’s (MAAT) stock price is €6.36 and MaaT Pharma’s (MAAT) 100-day simple moving average is 7.65, creating a Sell signal.
MaaT Pharma’s (MAAT) stock price is €6.36 and MaaT Pharma’s (MAAT) 200-day simple moving average is 7.54, creating a Sell signal.

MaaT Pharma (MAAT) Technical Indicators

Mar 03, 2025, 11:59 PM
Name
Value
Implied Action
RSI (14)
21.81
Buy
STOCH (9,6)
2.20
Buy
STOCHRSI (14)
1.73
Buy
MACD (12,26)
-0.35
Buy
ADX (14)
23.67
Neutral
Williams %R
-96.61
Buy
CCI (14)
-147.07
Buy
ATR (14)
0.23
-
Ultimate Oscillator
21.72
Sell
ROC
-13.11
Sell
MaaT Pharma’s (MAAT) Relative Strength Index (RSI) is 21.81, creating a Buy signal.
MaaT Pharma’s (MAAT) Trend Strength Indicator (ADX) is 23.67, creating a Neutral signal.
MaaT Pharma’s (MAAT) Commodity Channel Index (CCI) is -147.07, creating a Buy signal.
MaaT Pharma’s (MAAT) Price Rate of Change (ROC) is -13.11, creating a Sell signal.

FAQ

Is MAAT a Buy, Hold, or Sell?
Based on MAAT’s technical indicators, MAAT is a Sell.
    What is MAAT’s RSI (14)?
    MAAT’s RSI (14) is 21.81, which suggests MAAT is a Buy.
      What is MAAT’s MACD?
      MAAT’s MACD is -0.35, which suggests MAAT is a Buy.
        What is MAAT’s 5-day moving average?
        MAAT’s 5-day moving average is 6.54, which suggests MAAT is a Sell.
          What is MAAT’s 20-day moving average?
          MAAT 20-day moving average is 7.05, which suggests MAAT is a Sell.
            What is MAAT’s 50-day moving average?
            MAAT’s 50-day moving average is 7.66, which suggests MAAT is a Sell.
              What is MAAT’s 200-day moving average?
              MAAT’s 200-day moving average is 7.54, which suggests MAAT is a Sell.
                What is MAAT’s Williams % R (14)?
                MAAT’s Williams % R (14) is -96.61, which suggests MAAT is a Buy.
                  What is MAAT’s CCI (14)?
                  MAAT’s CCI (14) is -147.07, which suggests MAAT is a Buy.
                    What is the share price of MaaT Pharma?
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis